SCHEMBL5237110

SCHEMBL5237110

CNC1CC(=O)N(C)C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
GAA P10253 3/20 0.49
KDM4E B2RXH2 3/20 0.49
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KMT2A Q03164 3/20 0.45
LMNA P02545 3/20 0.45
MEN1 O00255 2/20 0.45
TSHR P16473 2/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
RECQL P46063 2/20 0.43
THRB P10828 1/20 0.43
HTT P42858 1/20 0.43
CYP19A1 P11511 1/20 0.39
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14463511 1.00 ALDH1A1 (0.49) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL5240143 0.98 ALDH1A1 (0.47) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
SCHEMBL16378120 0.80 ALDH1A1 (0.47) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
SCHEMBL12994836 0.80 ALDH1A1 (0.47) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
SCHEMBL21734377 0.78 ALDH1A1 (0.36) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
SCHEMBL23978582 0.77 ALDH1A1 (0.45) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
SCHEMBL13317748 0.77 KMT2A (0.53) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
SCHEMBL16925898 0.76 ALDH1A1 (0.33) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
SCHEMBL15872076 0.76 KDM4E (0.31) ALDH1A1GAAKDM4EMAPTSMN1; SMN2
SCHEMBL21895951 0.75 CYP1A2 (0.47) ALDH1A1GAAKDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758583-A2 ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-03-07 EP claimed
WO-2005118537-A2 ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2005-12-15 WO claimed
EP-3405010-B1 MULTILAYER TRANSMISSION LINE PLATE RESONAC CORP (JP) 2024-06-26 EP disclosed
EP-3154997-B9 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2021-04-14 EP disclosed
EP-2637694-B1 CONJUGATES OF AN IL-2 MOIETY AND A POLYMER NEKTAR THERAPEUTICS (US) 2021-04-07 EP disclosed
US-10957964-B2 Multilayer transmission line plate SHOWA DENKO MATERIALS CO., LTD. (JP) 2021-03-23 US disclosed
EP-3154997-B1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2020-02-19 EP disclosed
EP-2922575-B1 TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF HARVARD COLLEGE (US) 2019-06-26 EP disclosed
US-10328141-B2 Synthetic vaccines against Streptococcus pneumoniae type 1 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2019-06-25 US disclosed
US-20190023899-A1 MULTILAYER TRANSMISSION LINE PLATE RESONAC CORPORATION (JP) 2019-01-24 US disclosed
EP-2482855-B1 OLIGOMER-CALCIMIMETIC CONJUGATES AND RELATED COMPOUNDS NEKTAR THERAPEUTICS (US) 2017-12-27 EP disclosed
US-7767699-B2 Therapeutic agents useful for treating pain PURDUE PHARMA, L.P. (US) 2010-08-03 US disclosed
US-7767699-B2 Therapeutic agents useful for treating pain PURDUE PHARMA, L.P. (US) 2010-08-03 US disclosed
EP-1641775-B1 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN EURO CELTIQUE SA (LU) 2009-02-18 EP disclosed
US-7470753-B2 Silicone-modified antimicrobial polymer, antimicrobial agent and antimicrobial resin composition CHISSO CORPORATION (JP) 2008-12-30 US disclosed
US-7470753-B2 Silicone-modified antimicrobial polymer, antimicrobial agent and antimicrobial resin composition CHISSO CORPORATION (JP) 2008-12-30 US disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-7256251-B2 Methods of synthesis of polymers and copolymers from natural products FOLIA INC. (US) 2007-08-14 US disclosed
EP-1477512-B1 Silicone-modified antimicrobial polymer, antimicrobial agent and antimicrobial resin composition CHISSO CORP (JP) 2007-07-25 EP disclosed
WO-2005007641-A1 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2005-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10328141-B2 Synthetic vaccines against Streptococcus pneumoniae type 1 NEU1, ALG1, CSGALNACT1 ALDH1A1 3507/4885GAA 625/4885KDM4E 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.